Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

3.1K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.1K
Clinical Trials01:16

Clinical Trials

6.9K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
6.9K
Blinding01:11

Blinding

2.5K
Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
2.5K
Preclinical Development: Overview01:28

Preclinical Development: Overview

4.5K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.5K
Diversity in Cell Signaling Responses01:22

Diversity in Cell Signaling Responses

6.6K
The physiological function of a cell and cellular communication are outcomes of a range of extrinsic signals, intracellular signaling pathways, and cellular responses. No two cell types express the same repertoire of signaling components. Receptors are highly selective for their cognate ligands, but once activated, they can alter multiple cellular processes such as DNA transcription, protein synthesis, and metabolic activity. 
Graded and Abrupt Responses
Some signaling systems generate...
6.6K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

156
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
156

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Advancing the Science of Patient Input in Drug Research and Development.

Journal of participatory medicine·2026
Same author

Determinants of publication likelihood and timeliness for clinical studies.

Journal of clinical and translational science·2026
Same author

Cannabinoid Use Among Adult Women: A Scoping Review.

Journal of women's health (2002)·2025
Same author

Coping Together: A Qualitative Study Exploring the Work of Home Health Care Assistants in Ireland.

Geriatrics (Basel, Switzerland)·2025
Same author

Exploring Shifts in Prescription Dispensing Patterns: A Descriptive Analysis before and During the Initial Year of the COVID-19 Pandemic by Sex and Age.

Journal of women's health (2002)·2025
Same author

Enhancing Cardiovascular Health in Southeastern United States for Underrepresented Racial and Ethnic Minorities With HIV: A Qualitative Inquiry Using the Health Belief Model.

The Journal of the Association of Nurses in AIDS Care : JANAC·2025

Related Experiment Video

Updated: Aug 14, 2025

A Novel Method for Involving Women of Color at High Risk for Preterm Birth in Research Priority Setting
14:43

A Novel Method for Involving Women of Color at High Risk for Preterm Birth in Research Priority Setting

Published on: January 12, 2018

11.9K

Enhancing Diversity and Inclusion in Clinical Trials.

Amy Corneli1,2,3, Emily Hanlen-Rosado1, Kevin McKenna1

  • 1Department of Population Health Sciences, Duke University School of Medicine, Durham, North Carolina, USA.

Clinical Pharmacology and Therapeutics
|January 11, 2023
PubMed
Summary
This summary is machine-generated.

To improve clinical trial outcomes and advance health equity, research organizations must implement systemic, organizational-level changes to ensure diverse patient participation. This involves commitment, partnerships, accountability, and resources for inclusive clinical trials.

More Related Videos

Using Visual and Narrative Methods to Achieve Fair Process in Clinical Care
14:32

Using Visual and Narrative Methods to Achieve Fair Process in Clinical Care

Published on: February 16, 2011

23.8K
Bridging the Technology Divide in the COVID-19 Era: Using Virtual Outreach to Expose Middle and High School Students to Imaging Technology
09:55

Bridging the Technology Divide in the COVID-19 Era: Using Virtual Outreach to Expose Middle and High School Students to Imaging Technology

Published on: September 28, 2022

1.7K

Related Experiment Videos

Last Updated: Aug 14, 2025

A Novel Method for Involving Women of Color at High Risk for Preterm Birth in Research Priority Setting
14:43

A Novel Method for Involving Women of Color at High Risk for Preterm Birth in Research Priority Setting

Published on: January 12, 2018

11.9K
Using Visual and Narrative Methods to Achieve Fair Process in Clinical Care
14:32

Using Visual and Narrative Methods to Achieve Fair Process in Clinical Care

Published on: February 16, 2011

23.8K
Bridging the Technology Divide in the COVID-19 Era: Using Virtual Outreach to Expose Middle and High School Students to Imaging Technology
09:55

Bridging the Technology Divide in the COVID-19 Era: Using Virtual Outreach to Expose Middle and High School Students to Imaging Technology

Published on: September 28, 2022

1.7K

Area of Science:

  • Clinical research
  • Health equity
  • Regulatory science

Background:

  • Historically, women and racial/ethnic minorities are under-represented in U.S. clinical trials.
  • Inadequate representation limits understanding of new medical product safety and efficacy across diverse populations.
  • This disparity can worsen health inequities and limit the generalizability of trial findings.

Purpose of the Study:

  • To explore organizational-level practices that promote diversity and inclusion in clinical trials.
  • To identify systemic changes needed for sustainable support of diversity in clinical research.
  • To develop a framework for improving equitable access and diverse patient participation.

Main Methods:

  • Interviews with leaders at clinical trial conducting institutions.
  • Convened an expert meeting to discuss findings and provide guidance.
  • Developed a framework based on interview and expert input.

Main Results:

  • Leaders cited ethical imperatives, staff investment, resource allocation, and scientific benefits as motivations.
  • Cost and time were identified as key deterrents to implementing diversity initiatives.
  • A framework was developed, highlighting four key areas: commitment, partnerships, accountability, and resources.

Conclusions:

  • Systemic, organizational-level approaches are crucial for advancing diversity and inclusion in clinical trials.
  • Implementing strategies focused on commitment, partnerships, accountability, and resources can improve equitable access.
  • These changes are essential for achieving health equity and ensuring medical products benefit all populations.